SOURCE: Novo Nordisk A/S
FOR UK MEDICAL MEDIA ONLY <br><br> Phase 3a data demonstrates efficacy and tolerability of IDegLira (insulin degludec/liraglutide; Xultophy®) in adults with type 2 diabetes
IDegLira demonstrated a mean HbA1c reduction of 1.9% from baseline, versus 0.9% with insulin degludec. Sixty percent of people treated with IDegLira achieved the HbA1c goal of less than 53mmol/mol (˂7.0%) compared to 23% treated with insulin degludec (p<0.0001). People treated with IDegLira had a significant mean weight loss of 2.7 kg from baseline compared to no change with insulin degludec (p<0.0001). Forty percent of the people treated with IDegLira, achieved the HbA1c goal with no confirmed hypoglycaemic episodes and with no weight gain, compared to 8.5% of people treated with insulin degludec (p<0.0001).